跳至主要内容
临床试验/NCT02165085
NCT02165085已完成不适用

Identification of Plasmatic Biomarkers in Vascular Ehlers-Danlos Syndrome

Assistance Publique - Hôpitaux de Paris1 个研究点 分布在 1 个国家目标入组 211 人开始时间: 2013年6月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
211
试验地点
1
主要终点
Diagnostic value of plasma biomarkers SEDv

研究概览

简要总结

The purpose of this study is to determine whether patients with vascular Ehlers-Danlos syndrome present significant and specific changes of arterial endothelial and smooth muscular cell signalling/secretion, in comparison to matched healthy volunteers and patients with spontaneous arterial dissections.

详细描述

Vascular Ehlers-Danlos syndrome is a rare inherited disease which confers exceptional organ fragility in seamingly healthy young adults. The disease is caused by a mutation in the COL3A1 gene encoding type III collagen, critical to ensure physical resistance to mechanical stress of hollow organs. The disease results in increased tissular fragility, responsible of spontaneous arterial ruptures and dissections and spontaneous bowel perforations. The life-expectancy of patients with vascular Ehlers-Danlos syndrome is reduced by these recurring accidents. The exact mechanisms that trigger arterial accidents are unknown. Recent findings suggest a possible deleterious effect of inflammation and a possible dysregulation of the TGF-beta pathway. Thus, the purpose of this study is to identify further alterations in vascular endothelial and smooth muscular cell signalling/secretion, and to confirm previously suggested mechanisms of arterial accidents in vEDS patients.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Prospective

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with vascular Ehlers-Danlos syndrome must have been positively tested for a pathogenic mutation within the COL3A1 gene.
  • In patients with arterial dissection(s) any associated systemic arterial disease must have been ruled out, especially vascular Ehers-Danlos syndrome

排除标准

  • All subjects must not present any chronic systemic disease, any acute disease within seven days prior to enrollment, diabetes mellitus and arterial hypertension.

结局指标

主要结局

Diagnostic value of plasma biomarkers SEDv

时间窗: At the end of study (2 years after period of inclusion for first patient)

Analysis of the diagnostic value of different levels of plasma concentrations of microRNAs

次要结局

  • Reference value of biomarkers(At the end of study (2 years after period of inclusion for first patient))

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验